Core Insights - WuXi AppTec (603259.SH/2359.HK) presented at the 44th JPM Healthcare Conference, updating on its business progress [1] Business Development - The company’s small molecule API synthesis capacity reached 4 million liters by the end of 2025, indicating a robust commercial supply system built over 25 years [1] - As of Q3 last year, WuXi AppTec's small molecule CDMO pipeline totaled 3,430, with 80 commercial molecules, representing 16% of the global clinical stage small molecule new drugs [1] Financial Performance - WuXi AppTec expects a revenue of approximately 45.456 billion yuan for the full year 2025, a year-on-year increase of 15.84%, with a 21.4% growth in continuing operations revenue [1] - The profit performance is particularly strong, with a projected net profit attributable to shareholders of about 19.151 billion yuan, a significant year-on-year increase of 102.65% [1] - Adjusted non-IFRS net profit is expected to be around 14.957 billion yuan, up 41.33% year-on-year, while the net profit after deducting non-recurring items is projected at approximately 13.241 billion yuan, a 32.56% increase year-on-year [1] - The pre-announcement data indicates that WuXi AppTec will achieve historical highs in revenue and the three profit metrics for 2025 [1]

利润端表现尤为突出，多项指标呈现高速增长：经调整non-IFRS归母净利润约149.57亿元，同比增长 41.33%；归母净利润约191.51亿元，同比大幅增长102.65%；扣非后归母净利润约132.41亿元，同比增 长32.56%。 据此次披露，药明康德2025年在营收及上述三大利润指标上均创下历史新高，展现出整体经营的强劲态 势与盈利质量的持续提升。 就在本周早些时候，药明康德发布了2025年度业绩预增公告。公告显示，公司全年预计实现营业收入约 454.56亿元，同比增长15.84%；其中持续经营业务收入同比增长21.4%，增长势头稳健。 2026年1月14日，药明康德(603259.SH/2359.HK)在第44届摩根大通医疗健康大会上发表主题演讲，根据 公司所披露的财务数据显示，公司2025年经调整non-IFRS利润率近33%，创历史新高。 ...

药明康德 ：将以每股1元人民币的价格配售5840万股新H股。 ...

药明康德：将以每股1元人民币的价格配售5840万股新H股。 ...

PresentationGood morning, everyone. I'm Yang Huang, China Healthcare analyst of JPMorgan based in Hong Kong. Welcome to the third day of our JPMorgan Healthcare Conference. This morning's session is going to be kicked off by WuXi AppTec, and we have WuXi AppTec Co-CEO, Dr. Minzhang Chen, who is going to give us a presentation. Dr. Chen?Minzhang ChenCo-CEO & Executive Director All right. Thank you, Yang. Good morning, everyone. Happy New Year. I'm glad to be here first today to kick off the day. I hope our p ...

Summary of WuXi AppTec FY Conference Call Company Overview - **Company**: WuXi AppTec (SEHK:02359) - **Industry**: Healthcare, specifically in the biopharmaceutical sector - **Conference Date**: January 14, 2026 Key Highlights - **Financial Performance**: - Preliminary estimates for 2025 indicate total revenue of **45.5 billion RMB**, a **21.4%** year-over-year growth in continuing operations [5] - Adjusted non-IFRS net profit reached **15 billion RMB**, with a net profit margin of **32.9%**, reflecting a **5.9 percentage point** improvement year over year [5][12] - Backlog exceeds **55 billion RMB**, positioning the company for sustainable future growth [5] - **CRDMO Model**: - WuXi AppTec operates an integrated CRDMO (Contract Research, Development, and Manufacturing Organization) platform, supporting every stage of drug R&D from discovery to commercial manufacturing [4][17] - The company has expanded its total reactor volume for small molecule APIs to over **4 million liters** and solid phase peptide synthesizer capacity to over **100,000 liters** [4] - **Customer Engagement**: - The company has collaborated with nearly **6,000 partners** across more than **30 countries** [4] - Supported **21%** of small molecule new drugs approved by the FDA over the past five years, with a **27%** share of new drugs approved in 2025 [10] Industry Dynamics - **Challenges in Biotech**: - The industry faces long development cycles, high costs, and low success rates, leading to unmet clinical needs [2] - Biotech companies are under pressure to advance drug pipelines quickly to create value [2] - **Market Trends**: - There is a rebound in biotech funding, particularly benefiting early-stage businesses [39] - The demand for GLP-1 drugs is notably high, contributing to the company's financial performance [30] Operational Insights - **Capacity Utilization**: - The Tides business has seen significant capacity utilization, with plans to increase capacity further in 2026 [22][25] - The company is also expanding capabilities in oligonucleotides and small molecules alongside peptides [44] - **Quality Assurance**: - In 2025, the company completed **740 quality audits** with a 100% pass rate, reflecting its commitment to high standards [16][19] Future Outlook - **Guidance for 2026**: - The company anticipates that 2026 will at least match the performance of 2025, with official guidance to be provided on March 24, 2026 [31] - **Sustainability and ESG Initiatives**: - WuXi AppTec achieved the highest AAA rating from MSCI and improved its CDP Climate Change rating to A, reflecting its commitment to sustainability [15] Additional Considerations - **Investment in Talent and CapEx**: - The company plans to maintain a CapEx range of **5.5 billion to 6 billion RMB** in 2025, focusing on capabilities and talent retention [13][36] - **Impact of Currency Fluctuations**: - The company is monitoring the impact of RMB appreciation on its overseas business, with strategies in place to mitigate risks [33][35] This summary encapsulates the key points discussed during the WuXi AppTec FY Conference Call, highlighting the company's financial performance, operational strategies, and industry dynamics.

突破1.68万亿元，新年以来，无锡A股板块市值再创新高。同时，2025年，无锡在A股市场的融资规模创新高，并居全省第一。 其中，药明康德（603259）市值以2944亿元位居榜首，逼近3000亿元大关。 无锡板块在资本市场的高光表现，不仅体现在市值规模与排名的历史性突破上，更离不开持续涌入的资本活水为其强劲成长提供的坚实支撑。 2025年，无锡上市公司通过IPO及再融资方式在资本市场募集资金总额高达547.18亿元，创下近年募资新高。其中，A股募资规模418亿元，募资金额全省 第一，彰显出无锡企业在资本市场的强劲吸引力与发展活力。 无锡市委金融办相关负责人介绍，随着港股市场持续升温，赴港上市企业数量不断增长，目前无锡共有港股上市企业28家，另有15家企业正在港交所排队 上市，其中大部分企业港股上市进程已进入"最后一公里"。 为更好地帮助无锡企业赴港上市，有关方面将常态化开展专项活动，通过政策引导、平台搭建、资源对接等多项举措，推动更多符合条件的企业加快上市 进程，助力"无锡板块"在国际资本市场上扬帆起航、行稳致远。 相关消息称，2026年1月12日，无锡市127家A股上市公司总市值收于16888.66亿元，单 ...

Group 1 - The pharmaceutical industry in A-shares is showing a recovery trend, with some companies exceeding performance expectations for 2025 [1][14] - WuXi AppTec expects revenue of approximately 45.456 billion yuan for 2025, a year-on-year increase of about 15.84%, and a net profit of approximately 19.151 billion yuan, a year-on-year increase of about 102.65% [1][15] - WuXi AppTec's performance is driven by stable growth in its main business and the sale of equity in three companies, generating nearly 5.6 billion yuan in revenue [1][15] Group 2 - WoHua Pharmaceutical anticipates a net profit between 80 million and 115 million yuan for 2025, representing a year-on-year increase of 119.76% to 215.90% [2][16] - The growth in WoHua's performance is attributed to the price-volume trade-off trend after the entry of its product into centralized procurement and the extension to outpatient markets [3][17] Group 3 - Kangchen Pharmaceutical expects a net profit between 14.5 million and 17.5 million yuan for 2025, a year-on-year increase of 243% to 315% [4][19] - The company attributes its performance to the absence of goodwill impairment provisions for 2025, following a decline in revenue from a previously acquired business [5][19] Group 4 - Baiaosaitu is projected to achieve a net profit growth of 249.5% in 2025, with expected revenue of 1.31 billion yuan, a year-on-year increase of 37.75% [6][20] - The company began to achieve commercial profitability in 2024, successfully turning around its financial performance [6][20] Group 5 - The Chinese pharmaceutical market is expected to see significant developments in 2026, with a focus on innovative drug research and business development (BD) [7][21] - China has become the second-largest market for innovative drug launches globally, with leading pharmaceutical companies showing R&D intensities close to global averages [7][21] Group 6 - The total value of innovative drug licensing transactions from China is expected to exceed 130 billion USD in 2025, indicating strong recognition of Chinese pipelines by overseas buyers [9][23] - The CXO service industry is recovering, with predictions that the market size will approach 100 billion USD in 2026, driven by increased demand from innovative drug development [9][23] Group 7 - The AI pharmaceutical sector is becoming increasingly active, with significant transactions and the listing of AI companies on stock exchanges [11][25] - The global market for AI solutions in healthcare is projected to grow from 13.7 billion USD in 2022 to 155.3 billion USD by 2030, highlighting the potential for companies in this space [13][27]

Core Viewpoint - WuXi AppTec is expected to achieve a revenue of approximately 45.5 billion yuan in 2025, reflecting a year-on-year growth of about 15.84%, driven by strong performance in its chemical business and TIDES operations [1] Group 1: Financial Performance - The company anticipates a non-GAAP net profit of around 13.2 billion yuan in 2025, representing a year-on-year increase of approximately 32.56% [1] - The net profit attributable to shareholders is projected to be about 19.1 billion yuan, showing a year-on-year growth of approximately 102.65%, with a net profit margin exceeding 40% [1] - Multiple core profit indicators are growing significantly faster than revenue, indicating improved operational efficiency and profit quality alongside scale expansion [1] Group 2: Market Reaction - Following the earnings forecast announcement, both A-shares and H-shares of WuXi AppTec saw a substantial increase, leading the gains in the A-share pharmaceutical sector, with the CSI Medical Index rising by 2.85% and the CS Innovative Drug Index by 2.37% [1] - This market reaction reflects a revaluation of the company's earnings certainty and long-term value [1] Group 3: Structural Support for Growth - The current growth of WuXi AppTec is attributed to business structure optimization and the release of scale effects, rather than merely relying on cyclical recovery [2] - The revenue growth of the continuing operations exceeds overall revenue growth, indicating strengthened competitiveness in core business [2] - Profit margins and cash generation capabilities are improving, showcasing the company's systematic advantages in cost control, resource allocation, and project execution [2] Group 4: Governance and Long-term Value - The company has actively responded to regulatory guidance by completing mid-term dividends, with cumulative dividends and buybacks reaching 20 billion yuan since its listing, averaging a dividend payout ratio of about 44% [3] - WuXi AppTec's robust performance amidst complex external environments is supported by its mature governance system and long-term strategic focus [3] - The management's foresight regarding industry trends and deep understanding of global customer needs contribute to sustained order growth, reflecting the company's core competitiveness [3] Group 5: Market Assessment Post-Reduction - Following the completion of a recent share reduction, the company's stock price remained stable, with the average reduction price estimated at around 89 yuan, significantly lower than the market price of 106.50 yuan on January 13 [4] - Investors who bought shares after the reduction announcement generally achieved positive returns, validating the notion that "earnings are the best stabilizer" [4] - As uncertainties are gradually resolved, market evaluations are shifting focus back to operational quality, cash flow capabilities, and long-term growth potential [4]

Core Viewpoint - WuXi AppTec is expected to exceed its revenue guidance for 2025, with projected total revenue between 43.5 billion and 44 billion yuan, showcasing the advantages of its CRDMO (Contract Research, Development, and Manufacturing Organization) model [1] Group 1: Revenue and Growth Projections - The company is focusing on its unique "integrated, end-to-end" CRDMO business model, which is driven by customer demand for empowerment and certainty [1] - The revenue for 2025 is projected to reach a new high, driven by the recovery of the global investment environment, steady capacity construction, and rapid growth in TIDES (Therapeutics, Inhalation, Drug Delivery, and Engineering Services) business [1] - The net profit forecasts for 2025-2027 have been raised to 19.15 billion, 15.35 billion, and 17.72 billion yuan respectively, with corresponding EPS of 6.42, 5.14, and 5.94 yuan per share [1] Group 2: Strategic Focus and Business Development - The company has sold 100% of its clinical services research business in China, including clinical CRO (Contract Research Organization) and SMO (Site Management Organization) businesses, to further concentrate on its CRDMO model [1] - This strategic move aims to accelerate the construction of global capabilities and capacity deployment [1] - The company maintains a "buy" rating with a projected PE ratio of 15.37 times for 2025 [1]